Hpathy Article| Miasms: A New Look Through Epigenetics - Part I by Manish Bhatia Introduction: Nearly 200 years ago, the founder of Homeopathy, Dr. Samuel Hahnemann found out that the effect of many diseases like Scabies, Gonorrhea and Syphilis can be present even after the acute infection is treated. He found out that this effect can be present in future generations also without the actual infection being acquired. This trans-generational effect manifested in the form of ‘disease predispositions’. He called these effects ‘Miasms’. The effect in the same generation was called ‘acquired miasm’ and the effect that was present in future generations was called ‘inherited miasm’. Epigenics
Commonly defined as the study of heritable changes in gene function that occur without a change in the DNA sequence, epigenetics is reshaping the way scientists look at traditional genetics. Following is a selection of online general information and review articles on this emerging field.
For decades, our view of heredity has been written in the language of DNA -- and genetic mutations and recombinations have driven most descriptions of how phenotypic traits are handed down from one generation to another. Yet, as is amply demonstrated in Science's special issue of 10 August 2001, recent discoveries in the field of epigenetics -- the study of heritable changes in gene function that occur without a change in the DNA sequence -- have blurred that neat picture, and are changing the way researchers think about heredity. Epigenetic mechanisms such as DNA methylation, histone acetylation, and RNA interference, and their effects in gene activation and inactivation, are increasingly understood to be more than "bit players" in phenotype transmission and development. And, with the prospect of human cloning now being actively discussed in some quarters, understanding the twists and turns of epigenetic inheritance has become especially important.
To provide an extra dimension to coverage in the 10 August 2001 special issue, we're launching a new epigenetics section here on the Science Functional Genomics Web site. On this page, you'll find a collection of links to interesting Web resources on chromatin, methylation, imprinting, and a variety of other topics with an epigenetics bend. Also, we've gathered together a selection some groundbreaking research papers, Reviews, and Perspectives published in Science over the past five years, in a special new epigenetics section of our Functional Genomics Research Archive.
Federal Ministry of Education & Research: Combining proteome-based technologies with epigenetics using renal cell carcinoma (RCC) as a model: Identification of RCC specific cancer antigenes for vaccine and antibody therapies
INTERSCIENCE: Epigenetics to proteomics: From yeast to brain
Purnima Bhargava *
Centre for Cellular and Molecular Biology (Council of Scientific and Industrial Research), Tarnaka, Hyderabad, India
email: Purnima Bhargava (email@example.com)
*Correspondence to Purnima Bhargava, Centre for Cellular and Molecular Biology (Council of Scientific and Industrial Research) Uppal Road, Tarnaka, Hyderabad, India Fax: +91-40-27160591
Funded by: Council of Scientific and Industrial Research, Govt. of India
ABSTRACT Brain is the most complex and least understood organ of the body. Recent research suggests that epigenetics of the brain may be behind the complex functions of this master organ. Yeast, the simplest eukaryote, had been the model for studying the complex physiology of higher eukaryotes, including humans. Current depth in understanding of mechanisms of gene regulation has been possible mainly because of the knowledge acquired by epigenetic studies on yeast while the research on the biochemistry and physiology of the brain has been tremendously benefitted by proteomic studies. The independent advances of research in both these fields are now converging. As the current understanding of epigenetics can be applied to understand the mysteries of normal brain function as well as various diseases, modern proteomic approaches can help find new therapeutic targets. Received: 1 July 2009; Revised: 31 July 2009; Accepted: 25 August 2009